Pituitary tumor transforming gene-1 haplotypes and risk of pituitary adenoma: a case-control study

Pituitary tumors are commonly encountered benign monoclonal adenomas that arise from cells of the anterior pituitary gland, accounting for approximately 15% of all diagnosed intracranial tumors [1]. These monoclonal tumors arise from highly differentiated cells expressing hormone gene products, including growth hormone, prolactin, adrenocorticotrophic hormone, thyroid-stimulating hormone, follicle-stimulating hormone and luteinizing hormone. Pituitary adenomas may be functional and actively secrete hormones, leading to characteristic clinical features such as acromegaly, Cushing's disease and hyperprolactinaemia. Commonly, they are non-functional, leading primarily to hypogonadism and compressive pituitary failure [1]. Previous longitudinal incidence surveys reported that the prevalence of pituitary adenoma had been steadily rising over the last decades [2, 3]. A latest epidemiological study based on a well-defined population in the UK reveals that the prevalence of pituitary adenoma is 77.6/100,000, about four-fold higher than previously thought [4].

Several genetic and epigenetic alterations have been observed in pituitary tumorigenesis. In addition to classic cancer genes [5, 6], there are a significant number of genetic or epigenetic alterations in pituitary tumors that target cell cycle regulators [7]. A completely new cell cycle pathway involved in pituitary oncogenesis is represented by pituitary tumor transforming gene-1 (PTTG1)/securin, an oncogenic molecule first identified in GH4 rat pituitary tumor cells [8]. Playing multiple roles in cell cycle regulation at different stages, PTTG1 is involved in the mitotic checkpoint that prevents abnormal chromosome segregation [7]. It is overexpressed in a variety of endocrine-related tumors, especially pituitary, thyroid, breast, ovarian, and uterine tumors, as well as nonendocrine-related cancers in the central nervous, pulmonary, and gastrointestinal systems [9]. Increased PTTG1 mRNA expression in pituitary tumor tissue has been confirmed in several studies [10, 11].

While many studies are focused on exploring the PTTG1-mediated tumorigenic mechanisms, none was conducted to study the association of genetic alterations in PTTG1 with the risk of pituitary adenoma. In the present study, we are the first to have investigated the association of individual PTTG1 SNPs or PTTG1 haplotypes with the risk of pituitary adenoma. To comprehensively study the genetic variants of PTTG1 associated with susceptibility to pituitary adenomas, we genotyped five PTTG1 haplotype-tagging SNPs (htSNP) using PCR-RFLP in a case-control study, which included 280 pairs of age-, gender- and geographically matched Han Chinese people. The five htSNPs, including one in the 5'-flanking region, three in the intronic regions, and one in the 3'-flanking region of the PTTG1 gene, appropriately capture all the common haplotype blocks reconstructed in HapMap Phase III data [12].

As this was an age- and gender-matched cases-control study, there was no significant difference in sex and age between pituitary adenomas patients and controls (Table 1), and therefore adjustment for age and sex was not needed in data analysis.

As shown in Table 2, among the five htSNPs, rs2910201 and rs3811999 were found to depart significantly from Hardy-Weinberg equilibrium in controls and therefore excluded from later analyses. No significant difference in allele and genotype frequencies at any of the remaining three polymorphic sites (rs1895320, rs2910200, and rs68827420) was observed between pituitary adenoma patients and controls (Table 3).

D' value and r ² for rs1895320, rs2910200, and rs6882742 were calculated according to the genotyping data reported in Table 3. The different degrees of LD between cases and controls are summarized in Table 4. LD maps measured by D' in cases and controls shows rs2910200 and rs6882742 were in LD with each other in both cases and controls (D' > 0.8) (Figure 1). Moreover, rs1895320 and rs2910200 had weaker LD in cases (D' = 0.012, r ² = 0.0) than in controls (D' = 1.0, r ² = 0.026) (Table 4; Figure 1). According to the genotyping data in pituitary adenoma patients and controls, 2-SNP haplotypes (rs1895320 and rs2910200; rs2910200 and rs68827420) were reconstructed (Table 5). Haplotypes with frequencies greater than 0.05 were subject to further analysis. As shown in Table 5, three 2-SNP haplotypes for rs1895320 and rs2910200 or for rs2910200 and rs6882742 accounted for 100% of the haplotypes in controls, respectively; the frequencies of all the 2-SNP haplotypes were not significantly different between pituitary adenoma patients and controls. In addition, no significant association was found between the 2-SNP haplotypes and histological classification of pituitary adenoma (data not shown).

Pituitary tumors are common intracranial neoplasms that cause significant morbidity through mass effects and/or inappropriate secretion of pituitary hormones [16]. The prevalence of pituitary adenoma has dramatically increased in the past decade [4].

PTTG1/securin is a vital component of the spindle checkpoint controlling faithful chromatid separation. It inhibits separase, the major effector for chromosome segregation during mitosis [17]. Overexpression of PTTG1 causes cell transformation and induces aneuploidy [18, 19], whereas either abundance or loss of it can lead to dysregulated G2/M checkpoint surveillance, resulting in abnormal mitosis and chromosomal instability. Absence of this gene results in a decrease in the incidence of pituitary tumors in pRB heterozygous mice, probably by triggering ARF/p53/p21-dependent senescence [20, 21]. In contrast, overexpression PTTG1 in the pituitary in transgenic mice leads to pituitary hyperplasia and focal microadenomas [22]. All the previous findings indicate that PTTG1 is required for pituitary tumorigenesis, which warrant our study to explore possible association of genetic alterations in PTTG1 with the risk of pituitary adenoma, using htSNP and haplotype analyses to comprehensively capture various genetic variants of PTTG1 in a Han Chinese population. However, our results revealed no significant association between individual PTTG1 htSNPs or reconstructed PTTG1 haplotypes and the risk of pituitary adenoma, suggesting that genetic variation in PTTG1 is not an imporant contributing factor to pituitary tumorigenesis. PTTG1 seems to promote pituitary tumor formation through a variety of other ways.

Zhang et al. reported that PTTG1 mRNA was overexpressed in more than 90% of all types of pituitary tumors [10]. Based on our results, it seems that the PTTG1 mRNA overexpression in pituitary adenoma is more likely through epigenetic mechanisms rather than variation in the DNA sequence of PTTG1. Holt et al. reported that PTTG1 was regulated by cyclin-dependent kinase (CDK)-mediated phosphorylation [23], suggesting a link between the control of the cell cycle by CDKs and PTTG1. Moreover, PTTG1 activates β-fibroblast growth factor, c-myc and cyclin D3 to enhance cell proliferation [24‐26], and interacts with Ku and p53 to participate in DNA damage/repair and apoptosis [27]. Interplay between PTTG1 and the cell signaling molecules, rather than DNA sequence variation in the PTTG1 gene, may actually play an important role in pituitary tumorigenesis. Nevertheless, individual SNP analysis and/or haplotype analysis on genes of the interaction partners of PTTG1, or on newly identified candidate genes involved in pathogenesis of pituitary adenoma, such as the bone morphogenetic protein-4 (BMP-4) gene and the RWD-containing sumoylation enhancer (RSUME) gene [28], may yield interesting results.

Though no significant association was found between PTTG1 haplotypes and the risk of pituitary adenoma, this is the first report on the association of individual PTTG1 SNPs or PTTG1 haplotypes with the risk of pituitary adenoma based on a solid study; it will provide an important reference for future studies on the association between genetic alterations in PTTG1 and the risk of pituitary adenoma or other tumors.